中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 11
Nov.  2013
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2013  >  29(11): 835-838

Effects of different anti- HIV therapies on progression of hepatitis C in HCV / HIV- coinfected patients

DOI: 10.3969/j.issn.1001-5256.2013.11.009

  • Department of Infectious Diseases, Shanghai Public Health Clinical Center

  • Received Date: 2012-11-28
  • Published Date: 2013-11-20
    Abstract
  • Objective To investigate the effect of protease inhibitors ( PIs) - or non- nucleoside reverse transcriptase inhibitors ( NNRTIs) - based therapy on the progression of hepatitis C in patients with hepatitis C virus ( HCV) / human immunodeficiency virus ( HIV) coinfection. Methods A total of 273 patients initially diagnosed with HCV / HIV coinfection were enrolled and divided into PIs group ( n = 135) and NNRTIs group ( n = 138) to receive PIs- based therapy and NNRTIs- based therapy, respectively, for one year. Laboratory indices, such as HCV RNA, aspartate aminotransferase ( AST) , alanine aminotransferase ( ALT) , total bilirubin ( TBil) , albumin ( Alb) , laminin ( LN) , cholyglycine ( CG) , type III procollagen ( PCIII) , type IV collagen ( CIV) , prothrombin activity ( PTA) , and cholinesterase ( CHE) , were quantified before and after treatment. The obtained data were analyzed using SPSS 11. 5 software; enumeration data were analyzed using the Kolmogorov- Smirnov test, and non- normal data were analyzed using the Mann- Whitney U test. Results After the end of treatment, PTA, CHE, TBil, Alb, ALT, AST, CG, and LN levels were significantly higher in NNRTIs group than in PIs [PTA: 77% ( 67%-109%) vs 68% ( 56%-91%) ; CHE: 6717. 00 U/L ( 5951. 00-7622. 00 U/L) vs 5862. 00 U/L ( 4392. 00- 8539. 25 U/L) ;TBil: 10. 95 μmol / L ( 8. 10- 14. 32 μmol / L) vs 8. 60 μmol / L ( 8. 00- 9. 50 μmol / L) ; Alb: 43. 90 mmol / L ( 39. 65- 48. 20 mmol / L) vs 38. 90 mmol / L ( 36. 00- 45. 00 mmol / L) ; ALT: 52. 50 U / L ( 30. 00- 93. 50 U / L) vs 36. 20 U / L ( 30. 30- 40. 40 U / L) ; AST: 49. 00U /L ( 33. 00- 80. 00 U / L) vs 31. 30 U / L ( 29. 70- 38. 70 U / L) ; CG: 16. 78 μg / ml ( 3. 26- 29. 32 μg / ml) vs 3. 26 μg / ml ( 1. 02-6. 88 μg / ml) ; LN: 34. 40 ng / ml ( 16. 71- 46. 54 ng / ml) vs 34. 05 ng / ml ( 33. 42- 64. 33 ng / ml) ; P < 0. 01 or P < 0. 05]. Conclusion NNRTIs- based therapy can accelerate the progression of hepatitis C in HCV / HIV- coinfected patients.

     

    • FullText(HTML)
  • loading
    • References(1)
  • [1]MACíAS J, BERENGUER J, JAPN MA, et al.Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus[J].Hepatology, 2009, 50 (4) :1056-1063.[2]GRüNHAGE F, WASMUTH JC, HERKENRATH S, et al.Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C between HIV-negative and HIV-positive patients on HAART[J].Eur J Med Res, 2010, 15 (4) :139-144.[3]AIDS Study Group, Chinese Society of Infectious Diseases, Chinese Medical Association.HIV/AIDS management guidelines (2011) [J].Chin J Infect Dis, 2011, 29 (10) :629-640. (in Chinese) 中华医学会感染病分会艾滋病学组.艾滋病诊疗指南 (2011版) [J].中华传染病杂志, 2011, 29 (10) :629-640.[4]Chinese Society of Hepatology, Chinese Society of Infectious Diseases and Parasitology, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C[J].J Clin Hepatol, 2004, 20 (4) :197-203. (in chinese) 中华医学会肝病学分会, 中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南[J].临床肝胆病杂志, 2004, 20 (4) :197-203.[5]LI VECCHI V, SORESI M, COLOMBA C, et al.Transient elastography:a non-invasive tool for assessing liver fibrosis in HCV/HIV patients[J].World J Gastroenterol, 2010, 16 (41) :5225-5232.[6]Al-MOHRI H, MURPHY T, LU Y, et al.Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker[J].J Acquir Immune Defic Syndr, 2007, 44 (4) :463-469.[7]MORENO A, CERVERA C, FORTU'N J, et al.Epidemiology and outcome of infections in HIV/HCV-coinfected liver transplant recipients:A FIPSE/GESIDA prospective cohort study[J].Liver Transpl, 2012, 18 (1) :70-81.[8]LOKO MA, BANI-SADR F, WINNOCK M, et al.Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HCV/HIV-coinfected patients[J].J Viral Hepat, 2011, 18 (7) :e307-e314.[9]BLACKARD JT, SHERMAN KE.HCV/HIV co-infection:time to re-evaluate the role of HIV in the liver?[J].J Viral Hepat, 2008, 15 (5) :323-330.[10]SINGAL AK.Anand BSManagement of hepatitis C virus infection in HCV/HIV co-infected patients:clinical review[J].World J Gastroenterol, 2009, 15 (30) :3713-3724.[11]STERLING RK, WEGELIN JA, SMITH PG, et al.Similar progression of fibrosis between HCV/HIV-infected and HCV-infected patients:Analysis of paired liver biopsy samples[J].Clin Gastroenterol Hepatol, 2010, 8 (12) :1070-1076.[12]CONNOY A, TURNER J, NU'EZ M.Levels of serum markers of liver inflammation and fibrosis in patients with chronic hepatitis C virus infection according to HIV status and antiretroviral use[J].AIDS Res Hum Retroviruses, 2011, 27 (7) :719-725.[13]LUTZ P, WASMUTH JC, NISCHALKE HD, et al.Progression of liver fibrosis in HCV/HIV genotype 1 co-infected patients is related to the T allele of the rs12979860 polymorphism of the IL28B gene[J].Eur J Med Res, 2011, 16 (8) :335-341.[14]de BONA A, GALLI L, GALLOTTA G, et al.Rate of cirrhosis progression reduced in HCV/HIV co-infected non-responders to anti-HCV therapy[J].New Microbiol, 2007, 30 (3) :259-264.[15]INGILIZ P, VALANTIN MA, PREZIOSI P, et al.Influence of interferon-based therapy on liver fibrosis progression in HCV/HIV coinfected patients:A retrospective repeated liver biopsy analysis[J].J Hepatol, 2012, 56 (1) :49-54.[16]JANG JY, SHAO RX, LIN W, et al.HIV infection increases HCV-induced hepatocyte apoptosis[J].J Hepatol, 2011, 54 (4) :612-620.[17]TIEN PC, KOTLER DP, OVERTON ET, et al.Study of Fat Redistribution and Metabolic Change in HIV Infection Investigators.Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals[J].J Acquir Immune Defic Syndr, 2008, 48 (2) :1691-1676.[18]KELLEHER TB, MEHTA SH, BHASKAR R, et al.Prediction of hepatic fibrosis in HCV/HIV co-infected patients using serum fibrosis markers:the SHASTA index[J].J Hepatol, 2005, 43 (1) :78-84.[19]BARREIRO P, PINEDA JA, RALLAN N, et al.Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy[J].J Infect Dis, 2011, 203 (11) :1629-1636.[20]GARCíA-lVAREZ M, GUZMAN-FULGENCIO M, BERENGUER J, et al.European mitochondrial DNA haplogroups and liver fibrosis in HIV and hepatitis C virus coinfected patients[J].AIDS, 2011, 25 (13) :1619-1926.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2962) PDF downloads(606) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return